Last reviewed · How we verify
NCT04245683
Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population
trial testing Bowel/rectal resection in Rectal Cancer in 50 participants. Currently enrolling.
1 February 2027
Quick facts
| Lead sponsor | Bassett Healthcare |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 February 2020 |
| Primary completion | 1 February 2027 |
| Estimated completion | 1 August 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Bowel/rectal resection
- non-operative follow up
Conditions studied
- Rectal Cancer — all drugs for Rectal Cancer →
Sponsor
Bassett Healthcare — full company profile →
Who can join
18 and older, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational research study. Patients with rectal cancer can choose different courses of treatment. This study will follow these patients over the course of approximately six years, depending on their treatment. Patients will be monitored through clinic visits and survey assessments to see how they do, how they feel regarding their treatment choices, and their outcomes. The surveys will analyze the impact of the patients' treatment choices, as well as patient adherence, in a rural setting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04245683
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Cancer
Currently open trials in the same condition.
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
- NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting
Other Bassett Healthcare trials
Trials by the same sponsor.
- NCT04474288 — The COVID-19 PUI Reality Check (CPRC) Study · completed
- NCT04328012 — COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19 · Phase 2, PHASE3 · terminated
- NCT04327791 — COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1) · Phase 2, PHASE3 · unknown
- NCT04180943 — Liposomal Bupivacaine Versus Bupivacaine for for Postoperative Pain Control in Shoulder Surgery · Phase 4 · completed
- NCT03592082 — Use of Bismuth Subsalicylate in Clostridium Difficile Colitis · Phase 4 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04245683 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bassett Healthcare
- Last refreshed: 7 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04245683.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing